Figure 2. Kaplan-Meier curve for retreatment-free period after loading dose of ranibizumab.

We selected study participants who had received a loading dose of ranibizumab (3 × one-monthly injections, 0.5 mg), been treated as needed afterwards, and been followed up for more than 12 months. The duration from the third ranibizumab injection to the administration of additional treatment (event), or to the final visit by June 2014, or loss to follow up) was reported on a daily basis. A log-rank test revealed that the curves for pachychoroid neovasculopathy and neovascular AMD differed significantly from one another (p = 0.0095). Pachychoroid neovasculopathy showed longer retreatment-free period.